AFB/TB SUSCEPTIBILITY : 10 DRUG PANEL (COMBINATION OF 1ST AND 2ND LINE DRUGS)

AFB/TB Susceptibility: 10 Drug Panel (Combination of 1st and 2nd Line Drugs) is an advanced microbiology test used to determine the susceptibility or resistance of Mycobacterium tuberculosis to multiple anti-tuberculosis medications. The test evaluates the effectiveness of both first-line and second-line anti-TB drugs, helping clinicians select the most appropriate treatment regimen for patients with tuberculosis.

This comprehensive susceptibility panel is particularly valuable in cases of multidrug-resistant tuberculosis (MDR-TB), treatment failure, recurrent infection, and suspected drug-resistant TB. By identifying resistance patterns, the test helps optimize therapy, improve treatment outcomes, and reduce the spread of resistant tuberculosis strains.

Benefits of the Test

• Evaluates susceptibility to multiple anti-tuberculosis drugs.
• Detects resistance to first-line and second-line medications.
• Supports personalized TB treatment planning.
• Assists in managing MDR-TB and drug-resistant TB cases.
• Helps improve treatment success rates.
• Reduces unnecessary exposure to ineffective drugs.
• Provides valuable information for infectious disease specialists.
• Supports public health tuberculosis control efforts.

Why Doctors Recommend This Test

Doctors recommend this test when tuberculosis has been confirmed and there is concern about drug resistance. It is especially useful for patients with recurrent TB, treatment failure, persistent positive cultures, prior anti-TB therapy, or suspected multidrug-resistant tuberculosis.

The test helps clinicians identify the most effective medications and develop targeted treatment strategies based on the susceptibility profile of the infecting organism.

Preparation Before Test

• No fasting is required.
• Provide a properly collected respiratory specimen as instructed.
• Inform the doctor about previous tuberculosis treatment.
• Share details of current anti-TB medications.
• Ensure timely submission of samples to the laboratory.
• Follow all sample collection instructions carefully.

Normal Reporting Time

Most AFB/TB Susceptibility 10 Drug Panel reports at Focus Diagnostics are available within 2–3 hours after completion of laboratory processing; however, culture-based susceptibility testing may require additional incubation time depending on organism growth characteristics.

Who Should Take This Test?

This test may be recommended for:

• Patients with confirmed tuberculosis.
• Individuals with recurrent TB infection.
• Patients experiencing treatment failure.
• People suspected of multidrug-resistant TB.
• Individuals with persistent positive TB cultures.
• Patients exposed to drug-resistant TB cases.
• High-risk tuberculosis patients.
• Individuals requiring comprehensive susceptibility testing.

Detailed Information

Tuberculosis remains a major global health challenge, and the emergence of drug-resistant strains has significantly complicated treatment strategies. AFB/TB Susceptibility Testing using a 10 Drug Panel provides a detailed evaluation of how Mycobacterium tuberculosis responds to a range of anti-tuberculosis medications, including both first-line and second-line drugs.

Drug susceptibility testing plays a crucial role in tuberculosis management because resistance can develop due to incomplete treatment, inadequate medication regimens, poor adherence, or transmission of already resistant strains. Identifying resistance patterns early enables healthcare providers to avoid ineffective therapies and select the most appropriate medications.

The panel typically includes medications commonly used in standard TB treatment as well as second-line agents utilized in managing resistant infections. By assessing bacterial growth in the presence of these drugs, laboratory specialists can determine whether the organism is susceptible, resistant, or partially responsive to specific treatments.

This information is essential for managing multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), and complex tuberculosis cases requiring individualized treatment plans. Accurate susceptibility results help improve treatment success rates, reduce complications, and prevent ongoing transmission within communities.

The test is frequently recommended for patients who have failed standard treatment, experienced relapse, or have a history of exposure to resistant tuberculosis. Infectious disease specialists, pulmonologists, and public health authorities rely on susceptibility testing to guide evidence-based clinical decisions.

At Focus Diagnostics, AFB/TB Susceptibility Testing is performed using advanced microbiology techniques and strict quality control protocols to provide reliable, clinically relevant results that support effective tuberculosis management and patient care.